FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891570039> ?p ?o ?g. }

• W2891570039 abstract "Multiple-micronutrient (MMN) deficiencies often coexist among women of reproductive age in low- to middle-income countries. They are exacerbated in pregnancy due to the increased demands, leading to potentially adverse effects on the mother and developing fetus. Though supplementation with MMNs has been recommended earlier because of the evidence of impact on pregnancy outcomes, a consensus is yet to be reached regarding the replacement of iron and folic acid supplementation with MMNs. Since the last update of this Cochrane review, evidence from a few large trials has recently been made available, the inclusion of which is critical to inform policy.To evaluate the benefits of oral multiple-micronutrient supplementation during pregnancy on maternal, fetal and infant health outcomes.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (11 March 2015) and reference lists of retrieved articles and key reviews. We also contacted experts in the field for additional and ongoing trials.All prospective randomised controlled trials evaluating MMN supplementation during pregnancy and its effects on the pregnancy outcome were eligible, irrespective of language or the publication status of the trials. We included cluster-randomised trials, but quasi-randomised trials were excluded.Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. The quality of the evidence was assessed using the GRADE approach.Nineteen trials (involving 138,538 women) were identified as eligible for inclusion in this review but only 17 trials (involving 137,791 women) contributed data to the review. Fifteen of these 17 trials were carried out in low and middle-income countries and compared MMN supplements with iron and folic acid versus iron with or without folic acid. Two trials carried out in the UK compared MMN with a placebo. MMN with iron and folic acid versus iron, with or without folic acid (15 trials): MMN resulted in a significant decrease in the number of newborn infants identified as low birthweight (LBW) (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.85 to 0.91; high-quality evidence) or small-for-gestational age (SGA) (average RR 0.90, 95% CI 0.83 to 0.97; moderate-quality evidence), and a reduced rate of stillbirth (RR 0.91, 95% CI 0.85 to 0.98; high-quality evidence). No significant differences were shown for other maternal and pregnancy outcomes: preterm births (RR 0.96, 95% CI 0.89 to 1.03; high-quality evidence), maternal anaemia in the third trimester (RR 0.97, 95% CI 0.86 to 1.10), miscarriage (RR 0.89, 95% CI 0.78 to 1.01), maternal mortality (RR 0.97, 95% CI 0.63 to 1.48), perinatal mortality (RR 0.97, 95% CI 0.84 to 1.12; high-quality evidence), neonatal mortality (RR 0.98, 95% CI 0.90 to 1.07; high -quality evidence), or risk of delivery via a caesarean section (RR 1.03; 95% CI 0.75 to 1.43).A number of prespecified, clinically important outcomes could not be assessed due to insufficient or non-available data. Single trials reported results for: very preterm birth < 34 weeks, macrosomia, side-effects of supplements, nutritional status of children, and congenital anomalies including neural tube defects and neurodevelopmental outcome: Bayley Scales of Infant Development (BSID) scores. None of these trials reported pre-eclampsia, placental abruption, premature rupture of membranes, cost of supplementation, and maternal well-being or satisfaction.When assessed according to GRADE criteria, the quality of evidence for the review's primary outcomes overall was good. Pooled results for primary outcomes were based on multiple trials with large sample sizes and precise estimates. The following outcomes were graded to be as of high quality: preterm birth, LBW, perinatal mortality, stillbirth and neonatal mortality. The outcome of SGA was graded to be of moderate quality, with evidence downgraded by one for funnel plot asymmetry and potential publication bias.We carried out sensitivity analysis excluding trials with high levels of sample attrition (> 20%); results were consistent with the main analysis. We explored heterogeneity through subgroup analysis by maternal height and body mass index (BMI), timing of supplementation and dose of iron. Subgroup differences were observed for maternal BMI and timing of supplementation for the outcome preterm birth, with significant findings among women with low BMI and with earlier initiation of supplementation in the prenatal period. Subgroup differences were also observed for maternal BMI, maternal height and dose of iron for the outcome SGA, indicating a significant impact among women with higher maternal BMI and height, and with MMN supplement containing 30 mg of iron versus control receiving 60 mg of iron. The findings between subgroups for other primary outcomes were inconclusive. MMN versus placebo (two trials): A single trial in the UK found no clear differences between groups for preterm birth, SGA, LBW or maternal anaemia in the third trimester. A second trial reported the number of women with pre-eclampsia; there was no evidence of a difference between groups. Other outcomes were not reported.Our findings support the effect of MMN supplements with iron and folic acid in improving birth outcomes. The findings, consistently observed in several systematic evaluations of evidence, provide a strong basis to guide the replacement of iron and folic acid with MMN supplements containing iron and folic acid for pregnant women in developing countries where MMN deficiencies are common among women of reproductive age. Efforts should be focused on the integration of this intervention in maternal nutrition and antenatal care programs in developing countries." @default.
• W2891570039 created "2018-09-27" @default.
• W2891570039 creator A5020054157 @default.
• W2891570039 creator A5031009188 @default.
• W2891570039 date "2015-11-01" @default.
• W2891570039 modified "2023-10-16" @default.
• W2891570039 title "Multiple-micronutrient supplementation for women during pregnancy" @default.
• W2891570039 cites W1005224826 @default.
• W2891570039 cites W113793698 @default.
• W2891570039 cites W1425022928 @default.
• W2891570039 cites W142515901 @default.
• W2891570039 cites W1530782354 @default.
• W2891570039 cites W1541312440 @default.
• W2891570039 cites W1553221898 @default.
• W2891570039 cites W1564586420 @default.
• W2891570039 cites W1570838520 @default.
• W2891570039 cites W1579260873 @default.
• W2891570039 cites W1587466126 @default.
• W2891570039 cites W1604839202 @default.
• W2891570039 cites W1675337017 @default.
• W2891570039 cites W174055518 @default.
• W2891570039 cites W1785122941 @default.
• W2891570039 cites W1794647552 @default.
• W2891570039 cites W1812355893 @default.
• W2891570039 cites W1852799762 @default.
• W2891570039 cites W1879524379 @default.
• W2891570039 cites W1892263002 @default.
• W2891570039 cites W1893224485 @default.
• W2891570039 cites W1895969215 @default.
• W2891570039 cites W1897782272 @default.
• W2891570039 cites W1905952948 @default.
• W2891570039 cites W1905960148 @default.
• W2891570039 cites W1906159294 @default.
• W2891570039 cites W1910110103 @default.
• W2891570039 cites W1911987294 @default.
• W2891570039 cites W1915602451 @default.
• W2891570039 cites W1930588251 @default.
• W2891570039 cites W1933424639 @default.
• W2891570039 cites W1933466476 @default.
• W2891570039 cites W1945747909 @default.
• W2891570039 cites W1949591994 @default.
• W2891570039 cites W1950683579 @default.
• W2891570039 cites W1951167546 @default.
• W2891570039 cites W1959636718 @default.
• W2891570039 cites W1965147476 @default.
• W2891570039 cites W1966115319 @default.
• W2891570039 cites W1966756416 @default.
• W2891570039 cites W1966966289 @default.
• W2891570039 cites W1972055433 @default.
• W2891570039 cites W1976839711 @default.
• W2891570039 cites W1978929725 @default.
• W2891570039 cites W1984837674 @default.
• W2891570039 cites W1984841664 @default.
• W2891570039 cites W1986766737 @default.
• W2891570039 cites W1991215594 @default.
• W2891570039 cites W1997554397 @default.
• W2891570039 cites W1999968416 @default.
• W2891570039 cites W2004155368 @default.
• W2891570039 cites W2008145113 @default.
• W2891570039 cites W2009442982 @default.
• W2891570039 cites W2010300240 @default.
• W2891570039 cites W2011357571 @default.
• W2891570039 cites W2013352261 @default.
• W2891570039 cites W2019901458 @default.
• W2891570039 cites W2021002667 @default.
• W2891570039 cites W2021101256 @default.
• W2891570039 cites W2021278145 @default.
• W2891570039 cites W2025285659 @default.
• W2891570039 cites W2028917840 @default.
• W2891570039 cites W2030771384 @default.
• W2891570039 cites W2030978084 @default.
• W2891570039 cites W2031884773 @default.
• W2891570039 cites W2033170260 @default.
• W2891570039 cites W2035452438 @default.
• W2891570039 cites W2038616826 @default.
• W2891570039 cites W2039127851 @default.
• W2891570039 cites W2042907606 @default.
• W2891570039 cites W2044539581 @default.
• W2891570039 cites W2046735334 @default.
• W2891570039 cites W2050099237 @default.
• W2891570039 cites W2052314468 @default.
• W2891570039 cites W2053068530 @default.
• W2891570039 cites W2062521661 @default.
• W2891570039 cites W2064528921 @default.
• W2891570039 cites W2065182132 @default.
• W2891570039 cites W2070263459 @default.
• W2891570039 cites W2076136149 @default.
• W2891570039 cites W2076519071 @default.
• W2891570039 cites W2081588599 @default.
• W2891570039 cites W2085324843 @default.
• W2891570039 cites W2086057605 @default.
• W2891570039 cites W2086934744 @default.
• W2891570039 cites W2088041524 @default.
• W2891570039 cites W2089575651 @default.
• W2891570039 cites W2090323535 @default.
• W2891570039 cites W2097442349 @default.
• W2891570039 cites W2098799854 @default.
• W2891570039 cites W2098940363 @default.
• W2891570039 cites W2099002304 @default.
• W2891570039 cites W2099076759 @default.

• next